Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Portfolio News / By Karina Tin Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy Read More »
Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology Portfolio News / By Karina Tin Eikon Therapeutics Announces Nature Methods Publication Highlighting its Pioneering Oblique Line Scan Technology Read More »
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Portfolio News / By Karina Tin ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates Read More »
Nura Bio Expands Leadership Team with C-Suite Appointments Portfolio News / By Karina Tin Nura Bio Expands Leadership Team with C-Suite Appointments Read More »
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs Portfolio News / By Karina Tin Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs Read More »
NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer Portfolio News / By Karina Tin NGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical Officer Read More »
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Portfolio News / By Karina Tin Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Read More »
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones Portfolio News / By Karina Tin ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones Read More »
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Portfolio News / By Karina Tin Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Read More »
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Portfolio News / By Karina Tin ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations Read More »
